Dr. Reddy’s Laboratories Faces GST Penalty
Company Announcements

Dr. Reddy’s Laboratories Faces GST Penalty

Dr Reddy’s Laboratories (RDY) has released an update.

Dr. Reddy’s Laboratories Ltd. has been ordered to pay a tax demand including interest and penalty by the GST Authority, which the company received on August 30, 2024. The demand pertains to the financial years 2019-20 and 2020-21, concerning an alleged excess availed Input Tax Credit, resulting in a penalty of Rs.13,54,14,733. However, the company asserts that this will not materially impact its financials or operations, and plans to appeal the decision.

For further insights into RDY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskDr. Reddy’s Labs Faces Regulatory Setback in China
TheFlyDr. Reddy’s Atomoxetine Hydrochloride Capsules suspended in China
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!